Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation

Journal of Medicinal Chemistry

Volumn 43, Issue 1, 2000, Pages 1-18

  Sielecki, Thais M ^a   Boylan, John F ^a,b   Benfield, Pamela A ^a   Trainor, George L ^a  

^a DUPONT COMPANY   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINOCYCLOHEXYLAMINO) 6 (3,4 DICHLOROANILINO) 9 ETHYLPURINE; 2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE; 2 BIS(2 HYDROXYETHYL)AMINO 9 ISOPROPYL 6 (4 METHOXYBENZYLAMINO)PURINE; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 7 HYDROXYSTAUROSPORINE; ACETOPHTHALIDIN; AG 12268; AG 12275; ANTINEOPLASTIC AGENT; BOHEMINE; BUTYROLACTONE; CYCLIN DEPENDENT KINASE INHIBITOR; FASUDIL; FLAVOPIRIDOL; ISOPENTYLADENINE; K 252A; N METHYL 4 [2 (2 OXOPYRIDO[2,3 E]INDOL 3 YLIDENE)HYDRAZINO]PHENYLMETHANESULFONAMIDE; N METHYL 4 [2 (7 OXOTHIAZOLO[4,5 E]INDOL 8 YLIDENE)HYDRAZINO]BENZENESULFONAMIDE; OLOMOUCINE; OXINDOLE; PAULLONE; PURVALANOL; QUERCETIN; ROSCOVITINE; STAUROSPORINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; DOSE RESPONSE; DRUG DNA BINDING; DRUG RESEARCH; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; TARGET CELL;

EID: 0034642532     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990256j     Document Type: Review

References (189)

1. Foye, W. O. Cancer Chemotherapeutic Agents; American Chemical Society: Washington, DC, 1995.
2. Rowinsky, E. K. The Development and Clinical Utility of the Taxane Class of Antimicrotubule Chemotherapy Agents. Annu. Rev. Med. 1997, 48, 353-374.
3. Takimoto, C. H.; Wright, J.; Arbuck, S. G. Clinical Applications of the Camptothecins. Biochim. Biophys. Acta 1998, 1400, 107-119.
4. Ayral-Kaloustian, S.; Skotnicki, J. S. Ras Farnesyltransferase Inhibitors. Annu. Rep. Med. Chem. 1996, 31, 171-180.
5. Omura, S.; Sasaki, Y.; Iwai, Y.; Takeshima, H. Staurosporine, a Potentially Important Gift from a Microorganism. J. Antibiot. 1995, 48, 535-548.
6. Yasuzawa, T.; Lida, T.; Yoshida, M.; Hirayama, N.; Takahashi, M.; Shirahata, K.; Sano, H. The Structures of the Novel Protein Kinase C Inhibitors K-252a, b, c and d. J. Antibiot. 1986, 39, 1072-1078.
7. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase. Science 1994, 265, 1093-1095.
8. Fry, D. W. Recent Advances in Tyrosine Kinase Inhibitors. Annu. Rep. Med. Chem. 1996, 31, 151-160.
9. Garrett, M. D.; Fattaey, A. CDK Inhibition and Cancer Therapy. Curr. Opin. Genet. Dev. (England) 1999, 9, 104-111.
10. Webster, K. R. The Therapeutic Potential of Targeting the Cell Cycle. Exp. Opin. Invest. Drugs 1998, 7, 865-887.
11. Lees, J. A.; Weinberg, R. A. Tossing Monkey Wrenches into the Clock: New Ways of Treating Cancer. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4221-4223.
12. Hunter, T.; Pines, J. Cyclins and Cancer II: Cyclin D and CDK Inhibitors Come of Age. Cell 1994, 79, 573-583.
13. Pines, J. Cyclins and Cyclin-Dependent Kinases: Theme and Variations. Adv. Cancer Res. 1995, 55, 181-212.
14. Planas-Silva, M. D.; Weinberg, R. A. The Restriction Point and Control of Cell Proliferation. Curr. Opin. Cell Biol. 1997, 9, 768-772.
15. Murray, A. Cyclin-Dependent Kinases: Regulators of the Cell Cycle and More. Chem. Biol. 1994, 1, 191-195.
16. Kaldis, P. The CDK-Activating Kinase (CAK): From Yeast to Mammals. Cell. Mol. Life Sci. 1999, 55, 284-296.
17. Fisher, R. P.; Morgan, D. O. CAK in TFIIH: Crucial Connection or Confounding Coincidence? Biochim. Biophys. Acta 1996, 1288, 7-10.
18. Tsai, L. H.; Delalle, I.; Caviness Jr., V. S.; Chae, T.; Harlow, E. p35 is a Neural-Specific Regulatory Subunit of Cyclin-Dependent Kinase 5. Nature 1994, 371, 419-423.
19. Lew, J.; Huang, Q. Q.; Winkfein, R. J.; Aebersold, R.; Hunt, T.; Wang, J. H.; MRC Group in Signal Transduction, University of Calgary, Alberta, Canada. A Brain-Specific Activator of Cyclin-Dependent Kinase 5. Nature 1994, 371, 423-426.
20. Dou, Q. P.; Levin, A. H.; Zhao, S. Z.; Pardee, A. B. Cyclin E and Cyclin A as Candidates for the Restriction Point Protein. Cancer Res. 1993, 53, 1493-1497.
21. Zetterberg, A.; Larsson, O.; Woman, K. G. What is the restriction point? Curr. Opin. Cell. Biol. 1995, 7, 835-842.
22. Dowdy, S. F.; Hinds, P. W.; Louie, K.; Reed, S. I.; Arnold, A.; Weinberg, R. A. Physical Interaction of the Retinoblastoma Protein with Human D Cyclins. Cell 1993, 73, 499-511.
23. Pan, W.; Sun, T.; Hoess, R.; Grafstrom, R. Defining the Minimal Portion of the Retinoblastoma Protein that Serves as an Efficient Substrate for CDK4 Kinase/Cyclin D1 Complex. Carcinogenesis 1998, 19, 765-769.
24. Luo, R. X.; Postigo, A. A.; Dean, D. C. Rb Interacts with Histone Deacetylase to Repress Transcription. Cell 1998, 92, 463-473.
25. Chellappan, S.; Hiebert, S.; Mudryi, M.; Horowitz, J. M.; Nevins, J. R. The E2F Transcription Factor is a Cellular Target for the RB Protein. Cell 1991, 65, 1053-1061.
26. Brown, V. D.; Phillips, R. A.; Gallie, B. L. Cumulative Effect of Phosphorylation of pRB on Regulation of E2F Activity. Mol. Cell. Biol. 1999, 19, 3246-3256.
27. Sherr, C. J. Cancer Cell Cycles. Science 1996, 274, 1672-1677.
28. Jackson, P. K.; Chevalier, S.; Phillippe, M.; Kirschner, M. W. Early Events in DNA Replication Require Cyclin E and are Blocked by p21CIP1. J. Cell. Biol. 1995, 130, 755-769.
29. Zou, L.; Stillman, B. Formation of a Preinitiation Complex by S-phase Cyclin CDK-Dependent Loading of Cdc45p onto Chromatin. Science 1998, 280, 593-596.
30. Bartek, J.; Bartkova, J.; Lukas, J. The Retinoblastoma Protein Pathway and the Restriction Point. Curr. Opin. Cell. Biol. 1996, 8, 5-14.
31. ink4 Requires Functional Retinoblastoma Protein. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 6289-6293.
32. kip1 CDK "Inhibitors" are Essential Activators of Cyclin D-Dependent Kinases in Murine Fibroblasts. EMBO J. 1999, 18, 1571-1583.
33. Rane, S. G.; Dubus, P.; Mettus, R. V.; Galbreath, E. J.; Boden, G.; Reddy, E. P.; Barbacid, M. Loss of CAK4 Expression Causes Insulin-Deficient Diabetes and CAK4 Activation Results in β-Islet Cell Hyperplasia. Nat. Genet. 1999, 22, 44-52.
34. Lukas, J.; Bartkova, J.; Bartek, J. Convergence of Motigenic Signaling Cascades from Diverse Classes of Receptors at the Cyclin D-Cyclin-Dependent Kinase: pRb-Controlled G1 Checkpoint. Mol. Cell Biol. 1996, 16, 6917-6925.
35. Lacey, K.; Jackson, P. K.; Stearns, T. Cyclin-Dependent Kinase Control of Centrosome Duplication. Natl. Acad. Sci. U.S.A. 1999, 96, 2817-2822.
36. Krude, T.; Jackman, M.; Pines, J.; Laskey, R. A. Cyclin/Cdk-Dependent Initiation of DNA Replication in a Human Cell-Free System. Cell 1997, 88, 109-119.
37. Morgan, D. O.; De Bondt, H. L. Protein Kinase Regulation: Insights from Crystal Structure Analysis. Curr. Opin. Cell. Biol. 1994, 6, 239-246.
38. Berry, L. D.; Gould, K. L. Regulation of Cdc2 Activity by Phosphorylation at T14/Y15. Prog. Cell. Cycle Res. 1996, 2, 99-105.
39. Lowe, M.; Rabouille, C.; Nakamura, N.; Watsch, R.; Jackson, M.; Tamsa, E.; Rahman, D.; Pappin, D. J. C.; Warren, G. Cdc2 Kinase Directly Phosphorylates the Cis-Golgi Matrix Protein GM130 and is Required for Golgi Fragmentation in Mitosis. Cell 1998, 94, 783-793.
40. Morgan, D. O. Principles of CDK Regulation. Nature 1995, 375, 131-134.
41. DeBondt, H. L.; Rosenblatt, J.; Jancarik, J.; Jones, H. D.; Morgan, D. O.; Kim, S. H. Cyclins and Cyclin Dependent Kinases. Nature 1993, 363, 595-602.
42. Kelly, B. L.; Wolfe, K. G.; Roberts, J. M. Identification of a Substrate-Targeting Domain in Cyclin E for Phosphorylation of the Retinoblastoma Protein. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 2535-2540.
43. 1-to-S-Phase Transition. Mol. Cell. Biol. 1999, 19, 2690-2698.
44. King, R. W.; Deshaies, R. J.; Peters, J.; Kirschner, M. W. How Proteolysis Drives the Cell Cycle. Science 1996, 274, 1652-1658.
45. Yee, A.; Nichols, M. A.; Wu, L.; Hall, F. L.; Kobayashi, R.; Xiong, Y. Molecular Cloning of CDK7-associated Human MAT1, a Cyclin-Dependent Kinase-Activating Kinase (CAK) Assembly Factor. Cancer Res. 1995, 55, 6058-6062.
46. Gerber, M. R.; Farrell, A.; Deshaies, R. J.; Herskowitz, I.; Morgan, D. O. Cdc37 is Required for Association of the ProteinKinase cdc28 with G1 and Mitotic Cyclins. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 4651-4655.
47. Fattaey, A.; Harlow, E. New Functional Activities for the p21 Family of CDK Inhibitors. Genes Dev. 1997, 11, 847-862.
48. Fisher, R. P.; Morgan, D. O. Cell 1994, 78, 713-724.
49. Atherton-Fessler, S.; Hannig, G.; Piwnica-Worms, H. Reversible Tyrosine Phosphorylation and Cell Cycle Control. Semin. Cell. Biol. 1993, 4, 433-442.
50. Fattaey, A.; Booher, R. N. Mytl: A Weel-Type Kinase that Phosphorylates Cdc2 on Residue Thr14. Prog. Cell Cycle Res. 1997, 3, 233-240.
51. Draetta, G.; Eckstein, J. Cdc25 Protein Phosphatases in Cell Proliferation. Biochim. Biophys. Acta 1997, 1332, M53-M63.
52. Hoffman, I.; Karsenti, E. The Role of cdc25 in Checkpoints and Feedback Controls in the Eukaryotic Cell Cycle. J. Cell. Sci. Suppl. 1994, 18, 75-79.
53. 1, Cyclin-Dependent Kinases. Genes Dev. 1995, 9, 1149-1163.
54. Serrano, M.; Hannon, G. J.; Beach, D. A New Regulatory Motif in Cell-Cycle Control Causing Specific Inhibition of Cyclin D/CDK4. Nature 1993, 366, 704-707.
55. ink4a Inhibits Both CDK4- and CDK2-Associated Kinase Activity by Reassortment of Cyclin-CDK Inhibitor Complexes. Mol. Cell. Biol. 1999, 19, 1981-1989.
56. Hartwell, L. H.; Weinart, T. A. Checkpoints: Controls that Ensure the Order of Cell Cycle Events. Science 1989, 246, 629-634.
57. Reed, S. I. Control of the G1/S Transition. Cancer Surv. 1997, 29, 7-23.
58. Tourret, J.; McKeon, F. Tyrosine Kinases Weel and Mik1 as Effectors of DNA Replication Checkpoint Control. Prog. Cell Cycle Res. 1996, 2, 91-97.
59. Boddy, M. N.; Furnari, B.; Mondesert, O.; Russell, P. Replication Checkpoint Enforced by Kinases Cds1 and Chk1. Science 1998, 280, 909-912.
60. Huang, M.; Zhou, Z.; Elledge, S. J. The DNA Replication and Damage Checkpoint Pathways Induce Transcription by Inhibition of the Crtl Repressor. Cell 1998, 94, 595-605.
61. Zeng, Y.; Forbes, K. C.; Wu, Z.; Moreno, S.; Piwnica-Worms, H.; Enoch, T. Replication of Checkpoint Requires Phosphorylation of the Phosphates Cdc25 by Cds1 or Chk1. Nature 1998, 395, 507-510.
62. Amon, A. The Spindle Checkpoint. Curr. Opin. Genet. Dev. 1999, 9, 69-75.
63. Hardwick, K. G. The Spindle Checkpoint. Trends Genet. 1998, 14, 1-4.
64. Millard, S. S.; Koff, A. Cyclin-Dependent Kinase Inhibitors in Restriction Point Control, Genomic Stability and Tumorigenesis. J. Cell. Biochem. Suppl. 1998, 30, 37-42.
65. DelSal, G.; Loda, M.; Pagano, M. Cell Cycle and Cancer: Critical Events at the G1 Restriction Point. Crit. Rev. Oncogene 1996, 7, 127-142.
66. Sherr, C. J. Cancer Cell Cycles. Science 1996, 274, 1672-1677.
67. Hartwell, L. H.; Kastan, M. B. Cell Cycle Control and Cancer. Science 1994, 266, 1821-1828.
68. Hall, M.; Peters, G. Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer. Adv. Cancer Res. 1996, 56, 67-108.
69. Heintz, N. Cell Death and the Cell Cycle: A Relationship Between Transformation and Neurodegeneration? Trends Biochem. Sci. 1993, 18, 157-159.
70. Arendt, T.; Holzer, M.; Gartner, U.; Bruckner, M. K. Aberrancies in Signal Transduction and Cell Cycle Related Events in Alzheimer's Disease. J. Neural Transm. Suppl. 1998, 54, 147-158.
71. Wei, P.; Garber, M. E.; Fang, S.; Fischer, W. H.; Jones, K. A. A Novel CDK9-Associated C-Type Cyclin Interacts Directly with HIV-1 Tat and Mediates Its High-Affinity, Loop-Specific Binding to TAR RNA. Cell 1998, 92, 451-462.
72. Morgan, D. O. The Dynamics of Cyclin Dependent Kinase Structure. Curr. Opin. Cell Biol. 1996, 8, 767-772.
73. Kim, S.-H. Structure-based Inhibitor Design for CDK2, a Cell Cycle Controlling Protein Kinase. Pure Appl. Chem. 1998, 70, 555-565.
74. De Bondt, H. L.; Rosenblatt, J.; Jancarik, J.; Jones, H. D.; Morgan, D. O.; Kim, S.-H. Crystal Structure of Cyclin Dependent Kinase 2. Nature 1993, 363, 595-602.
75. Jeffrey, P. D.; Russo, A. A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massague, J.; Pavletich, N. P. Mechanism of CDK Activation Revealed by the Structure of a Cyclin A-CDK2 Complex. Nature 1995, 376, 313-320.
76. Meijer, L.; Kim, S. H. Chemical Inhibitors of Cyclin-Dependent Kinases. Methods Enzymol. 1997, 283, 113-128.
77. Mayrose, D. R.; Nichols, M. A.; Xiong, Y.; Ke, H. Purification and Crystallization of Cyclin-dependent Kinase Inhibitor p21. Protein Sci. 1996, 5, 1928-1930.
78. Ink4d. Nature 1997, 389, 999-1003.
79. Brotherton, D. H.; Dhanaraj, V.; Wick, S.; Brizuela, L.; Domaille, P. J.; Volyanik, E.; Xu, X.; Parisini, E.; Smith, B. O.; Archer, S. J.; Serrano, M.; Brenner, S. L.; Blundell, T. L.; Laue, E. D. Crystal Structure of the Complex of the Cyclin D-dependent kinase CDK6 Bound to the Cell Cycle Inhibitor p19INK4d. Nature 1998, 395, 244-250.
80. Fong, T. A. T.; Shawver, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) that Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types. Cancer Res. 1999, 59, 99-106.
81. R&D Focus 1997, Dec 15.
82. Singh, P.; Kumar, R. Inhibitors of the Epidermal Growth Factor Receptor Protein Tyrosine Kinase. A Quantitative Structure-Activity Relationship Analysis. J. Enzyme Inhib. 1998, 13, 125-134.
83. Gibson, K. H.; Brundy, W.; Godfrey, A. A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Epidermal Growth Factor Receptor Tyrosine Kinase: Structure-Activity Relationships and Antitumor Activity of Novel Quinazolines. Bioorg. Med. Chem. Lett. 1997, 7, 2723-2728.
84. Thompson, A. M.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Nelson, J. A.; Showalter, H. D. Hollis; Roberts, B. J.; Vincent, P. W.; Denny, W. A. Tyrosine Kinase Inhibitors. 13. Structure-Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. J. Med. Chem. 1997, 40, 3915-3925.
85. Bencteux, E.; Houssin, R.; Henichart, J. A short and Unequivocal Synthesis of 5-Aminotetrazolo[1,5-a]quinazoline as a Tricyclic Analogue of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035). J. Heterocycl. Chem. 1997, 34, 1375-1378.
86. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Persons, P. E.; Ly, C. Q.; Maguire, M. P.; Zulli, A. L.; Cheney, D. L.; Zilberstein, A.; Johnson, S. E.; Franks, C. F.; Mitchell, K. J. The Synthesis and SAR of New 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, Inhibitors of CSF-1R Tyrosine Kinase Activity. Bioorg. Med. Chem. Lett. 1997, 7, 421-424.
87. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Zulu, A. L.; Hsu, C. J.; Zilberstein, A.; Johnson, S. E.; Hook, L. E.; Jacoski, M. V. The Preparation and SAR of 4-(Anilino), 4-(Phenoxy), and 4-(Thiopnenoxy)-Quinazolines: Inhibitors of p561ck and EGF-R Tyrosine Kinase Activity. Bioorg. Med. Chem. Lett. 1997, 7, 417-420.
88. Newcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. J. Med. Chem. 1996, 39, 918-928.
89. R&D Focus 1997, Aug 11.
90. Furusaki, A.; Hashiba, N.; Matsumoto, T.; Hirano, A.; Iwai, Y.; Omura, S. The Crystal and Molecular Structure of Staurosporine, a New Alkaloid from a Streptomyces Strain. Bull. Chem. Soc. Jpn. 1982, 55, 3681-3685.
91. Meijer, L. Chemical Inhibitors of Cyclin-Dependent Kinases. Trends Cell. Biol. 1996, 6, 393-397.
92. Gadbois, D.; Hamaguchi, J. R.; Swank, R. A.; Bradbury, E. M.Staurosporine is a Potent Inhibitor of p34cdc2 and p34cdc2-like Kinases. Biochem. Biophys. Res. Commun. 1992, 184, 80-85.
93. Meijer, L. Chemical Inhibitors of Cyclin-Dependent Kinases. In Progress in Cell Cycle Research; Meijer, L., Guidet, S., Tung, H. Y. L., Eds.; Plenum Press: New York, 1995; Vol. 1, pp 351-361.
94. Lawrie, A. M.; Noble, M. E. M.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein Kinase Inhibition by Staurosporine Revealed in Details of the Molecular Interaction with CDK2. Nat. Struct. Biol. 1997, 4, 796-801.
95. Drug and Market Development 1997, May 1, 98-100.
96. Urano, M.; Reynolds, R.; Begley, J. Protein kinase C Inhibitor as a Potent Inhibitor of Accelerated Repopulation During Radiotherapy: I. Growth Inhibitory, Cytotoxic, and Indirect Radiosensitizing Effects of a Staurosporine Derivative (UCN-01) In Vitro. Radiat. Oncol. Invest. 1995, 3, 64-71.
97. Wang, Q.; Fan, S.; Eastman, A.; Worland, P. J.; Sausville, E. A.; O'Connor, P. M. UCN-01: A Potent Abrogator of G2 Checkpoint Function in Cancer Cells with Disrupted p53. J. Natl. Cancer Inst. 1996, 88, 956-965.
98. Akinaga, S.; Nomura, K.; Gomi, K.; Okabe, M. Enhancement of Antitumor Activity of Mitomycin C In Vitro and In Vivo by UCN-01, a Selective Inhibitor of Protein Kinase C. Cancer Chemother. Pharmacol. 1993, 32, 183-189.
99. Seynaeve, C. M.; Stetler, S. M.; Sebers, S.; Kaur, G.; Sausville, E. A.; Worland, P. J. Cell Cycle Arrest and Growth Inhibition by the Protein Kinase Antagonist UCN-01 in Human Breast Carcinoma. Cancer Res. 1993, 53, 2081-2086.
100. Bredel, M.; Pollack, I. F.; Freund, J. M.; Rusnak, J.; Lazo, J. S. 7-Hydroxystaurosporine (UCN-01), a Selective Inhibitor of Protein Kinase C, Blocks Malignant Glioma Growth by Inducing Apoptosis Independent of p53 and in a Time-Dependent manner. Proc. Am. Assoc. Cancer Res. 1997, 38, 500.
101. Schwartz, G. K.; Farsi, K.; Danso, D.; Dhupar, S. K.; Kelsen, D.; Spriggs, D. The Protein Kinase C (PKC) Inhibitors UCN-01 and Flavopiridol (FLAVO) Significantly Enhance the Cytotoxic Effect of Chemotherapy by Promoting Apoptosis in Gastric and Breast Cancer Cells. Proc. ASCO 1996, 15, 501.
102. Link, J. T.; Raghavan, S.; Gallant, M.; Danishefsky, S. J.; Chou, T. C.; Ballas, L. M. Staurosporine and ent-Staurosporine: The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles. J. Am. Chem. Soc. 1996, 118, 2825-2842.
103. Pereira, E. R.; Belin, L.; Sancelme, M.; Prudhomme, M.; Oilier, M.; Rapp, M.; Severe, D.; Riou, J.-F.; Fabbro, D.; Meyer, T. Structure-Activity Relationships in a Series of Substituted Indolocarbazoles: Topoisomerase I and Protein Kinase C Inhibition and Antitumoral and Antimicrobial Properties. J. Med. Chem. 1996, 39, 4471-4477.
104. Wood, J. L.; Stoltz, B. M.; Goodman, S. N.; Onwueme, K. Design and Implementation of an Efficient Synthetic Approach to Pyranosylated Indolocarbazoles: Total Synthesis of (+)-RK286c, (+)-MLR-52, (+)-Staurosporine, and (-)-TAN-1030a. J. Am. Chem. Soc. 1997, 119, 9652-9661.
105. Wood, J. L.; Stoltz, B. M.; Onwueme, K.; Goodman, S. N. The Synthesis of Desamido Analogues of Staurosporine, RK-286c, and TAN-1030a. Tetrahedron Lett. 1996, 37, 7335-7338.
106. Wood, L.; Stoltz, B. M.; Goodman, S. N. Total Synthesis of (+)-RK-286c, (+)-MLR-52, (+)-Staurosporine, and (+)-K252a. J. Am. Chem. Soc. 1996, 118, 10656-10657.
107. Ranelleti, F. O.; Ricci, R.; Larocca, L. M.; Maggiano, N.; Capelli, A.; Scamibia, G.; Benedett-Panici, P.; Mancuso, S.; Rumi, C.; Piantelli, M. Growth Inhibitory Effect of Quercetin and Presence of Type-II Estrogen-Binding Sites in Human Colon-Cancer Cell Lines and Primary Colorectal Tumors. Int. J. Cancer 1992, 50, 486-492.
108. NCI PDG Clinical Trial Search, November 1997.
109. R&D Drug News 1998, Jan 19.
110. Senderowicz, A. M.; Headlee, D.; Stinson, S. F.; Lush, R. M.; Kalil, N.; Villalba, L.; Hill, K.; Steinberg, S. M.; Figg, W. D.; Tompkins, A.; Arbuck, S. G.; Sausville, E. A. Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms. J. Clin. Oncol. 1998, 16, 2986-2999.
111. Mansuri, M. M.; Murthi, K. K.; Pal, K. Preparation of Analogues of Chromones as Inhibitors of Cyclin-Dependent Kinases. PCT Int. Appl. WO 9716447 A1 970509.
112. Sedlacek, H. H.; Czech, J.; Naik, R.; Kaur, G.; Worland, P.; Losiewicz, M.; Parker, B.; Carlson, B.; Smith, A. Flavopiridol (L86 8275; NSC 649890), a New Kinase Inhibitor for Tumor Therapy. Int. J. Oncol. 1996, 9, 1143-1168.
113. Carlson, B. A.; Dubay, M. M.; Sausville, E. A.; Brizuela, L.; Worland, P. J. Flavopiridol Induces G1 Arrest with Inhibition of Cyclin-Dependent Kinase CDK2 and CDK4 in Human Breast Carcinoma Cells. Cancer Res. 1996, 56, 2973-2978.
114. Losiewicz, M. D.; Carlson, B. A.; Kaur, G.; Sausville, E. A.; Worland, P. J. Potent Inhibition of CDC2 Kinase Activity by the Flavonoid L86-8275. Biochem. BioPhys. Res. Commun. 1994, 201, 589-595.
115. Schwartz, G. K.; Farsi, D.; Greaney, C.; Werner, J.; Kelsen, D. K. The protein Kinase C (PKC) Inhibitor Flavopiridol (FLAVO) Significantly Enhances the Cytotoxic Effect of Chemotherapy by Promoting Apoptosis in Gastric Cancer Cells. Prog. Gastric Res. 1997, 1, 627-629.
116. Czech, J.; Hoffman, D.; Naik, R.; Sedlacek, H. Antitumoral Activity of Flavone L 86-8275. Int. J. Oncol. 1995, 6, 31-36.
117. Arguello, F.; Alexander, M.; Sterry, J. A.; Tudor, G.; Smith, E. M.; Kalavar, N. T.; Greene, J. F. Jr.; Koss, W.; Morgan, C. D.; Stinson, S. F.; Siford, T. J.; Alvord, G.; Klabansky, R. L.; Sausville, E. A. Flavopiridol Induces Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and has Potent Antitumor Activity In Vivo Against Human Leukemia and Lymphoma Xenografts. Blood 1998, 91, 2482-2490.
118. Schwartz, G. K.; Farsi, D.; Greaney, C.; Werner, J.; Kelsen, D. K. The Protein Kinase C (PKC) Inhibitor Flavopiridol (FLAVO) Significantly Enhances the Cytotoxic Effect of Chemotherapy by Promoting Apoptosis in Gastric Cancer Cells. 2nd International Gastric Cancer Congress, Munich, Germany, Apr 27-30, 1997; pp 627-629.
119. Bible, K. C.; Kaufmann, S. H. Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: the Importance of Sequence of Administration. Cancer Res. 1997, 57, 3375-3380.
120. de Azevedo, W. F., Jr.; Mueller-Dieckmann, H.; Schulze-Gahmen, U.; Worland, P. J.; Sausville, E.; Kim, S. Structural Basis for Specificity and Potency of a Flavonoid Inhibitor of Human CDK2, a Cell Cycle Kinase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2735-2740.
121. Kim, S.; Schulze-Gahmen, U.; Brandsen, J.; Filgueira de Azevedo, W., Jr. Structural Basis for Chemical Inhibition of CDK2. Prog. Cell Cycle Res. 1996, 2, 137-145.
122. Kim, K. Preparation of 2-Thia-or 2-Oxa-flavopiridol Analogues for use as Protein Kinase Inhibitors. PCT Int. Appl. WO 9742949.
123. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J. Y.; Detivaud, L.; Leclerc, S.; Meijer, L. Inhibition of Cyclin-Dependent Kinases by Purine Analogues. Sur. J. Biochem. 1994, 224, 771-786.
124. Glab, N.; Labidi, N. H.; Qin, L. X.; Trehin, C.; Bergounioux, C.; Meijer, L. Olomoucine, an Inhibitor of the CDC2/CDK2 Kinases Activity, Blocks Plant Cells at the G1 to S and G2 to M Cell Cycle Transitions. FEES Lett. 1994, 353, 207-211.
125. Abraham, R. T.; Acquarone, M.; Andersen, A.; Asensi, A.; Belle, R.; Berger, F.; Bergounioux, C.; Brunn, G.; Buquet-Fagot, C.; Fagot, D.; Glab, N.; Goudeau, M.; Guerrier, P.; Houghton, P. J.; Hendriks, H.; Kloareg, B.; Lippai, M.; Marie, D.; Maro, B.; Meijer, L.; Mester, J.; Mulner-Lorillon, O.; Poulet, S. A.; Schierenberg, E.; Schutte, B.; Vaulot, D.; Verlhac, M. H. Cellular Effects of Olomoucine, an Inhibitor of Cyclinc-Dependent Kinases. Biol. Cell 1995, 83, 105-120.
126. Ongkeko, W.; Fergusson, J. P.; Harris, A. L.; Norbury, J. Inactivation of CDC2 Increases the Level of Apoptosis Induced by DNA Damage. J. Cell Sci. 1995, 108, 2897-2904.
127. Schutte, B.; Nieland, L.; van Engeland, M.; Henfling, M.; Meijer, L.; Ramaekers, F. The Effect of the Cyclin-Dependent Kinase Inhibitor Olomoucine on Cell Cycle Kinetics. Exp. Cell. Res. 1997, 236, 4-15.
128. Deazevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strand, M.; Kim, S. H. Inhibition of Cyclin-Dependent Kinases by Purine Analogues-Crystal Structure of Human CDK2 Complexed with Roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
129. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S. H. Multiple Modes of Ligand Recognition: Crystal Structures of Cyclin-Dependent Protein Kinase 2 in Complex with ATP and Two Inhibitors, Olomoucine and Isopentenyladenine. Proteins: Struct. Funct. Genet. 1995, 22, 378-391.
130. Hajduch, M. 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, June 16-19, 1998; Abstr. 522.
131. Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Espinoza, H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors. Science 1998, 281, 533-538.
132. Schow, S. R.; Mackman, R. L.; Blum, C. L.; Brooks, E.; Horsma, A. G.; Joly, A.; Kerwar, S. S.; Lee, G.; Shiffman, D.; Nelson, M. G.; Wang, X.; Wick, M. M.; Zhang, X.; Lum, R. T. Synthesis and Activity of 2,6,9-Trisubstituted Purines. Bioorg. Med. Chem. Lett. 1997, 7, 2697-2702.
133. Brooks, E. E.; Gray, N. S.; Joly, A.; Kerwar, S. S.; Lum, R.; Mackman, R. L.; Norman, T. C.; Rosete, J.; Rowe, M.; Schow, S. R.; Schultz, P. G.; Wang, X.; Wick, M. M.; Shiftman, D. CVT-313, a Specific and Potent Inhibitor of CDK2 that Prevents Neointimal Proliferation. J. Biol. Chem. 1997, 272, 29207-29211.
134. Lum, R. T.; Blum, C. L.; Mackman, R.; Wick, M. M.; Schow, S. R. Preparation of Purine Inhibitors of Cyclin Dependent Kinase 2 and IkB-a Kinase for use as Antitumor, Antiproliferative, and Leukemia Inhibiting Agents. PCT Int. Appl. WO 9805335 A1 980212.
135. Brooks, E. E.; Gray, N. S.; Joly, A.; Kerwar, S. S.; Lum, R.; Mackman, R. L.; Norman, T. C.; Rosete, J.; Rowe, M.; Schow, S. R.; Schultz, P. G.; Wang, X.; Wick, M. M.; Shiffman, D. CVT-313, a Specific and Potent Inhibitor of CDK2 that Prevents Neointimal Proliferation. J. Biol. Chem. 1997, 272, 29207-29211.
136. Legraverend, M.; Ludwig, O.; Bisagni, E.; Leclerc, S.; Merijer, L. Synthesis of C2 Alkynylated Purines, a New Family of Potent Inhibitors of Cyclin-Dependent Kinases. Bioorg. Med. Chem. Lett. 1998, 8, 793-798.
137. Kent, L. L.; Hull-Campbell, N. E.; Lau, T.; Wu, J. C.; Thompson, S. A.; Nori, M. Characterization of Novel Inhibitors of Cyclin-Dependent Kinases. Biochem. Biophys. Res. Commun. 1999, 260, 768-774.
138. Luzzio, M. J.; Bramson, N.; Dickerson, S.; Frye, S. V.; Harris, P.; Hassell, A. M.; Holmes, W.; Hunter, R.; Kuyper, L.; Lackey, K.; Lovejoy, B.; Montana, V.; Rocque, W.; Shewchuk, L.; Veal, J.; Walker, D. Inhibitors of Cyclin Dependent Kinases: Design, Synthesis & Evaluation. Am. Assoc. Cancer Res. 1999, Apr 10-14.
139. Davis, S. T.; Dickerson, S. H.; Frye, S. V.; Harris, P. A. Substituted Oxindole Derivatives as Protein Tyrosine Kinase and as Protein Serine/Threonine Kinase Inhibitors. PCT Int. Appl. W09915500 A1 990401.
140. Walker, D. H.; Luzzio, M.; Veal, J.; Dold, K.; Edelstein, M.; Parker, P.; Rusnak, D.; Emerson, D.; Miller, C.; Onori, J.; Bramson, H. N.; Harris, P.; Hunter, R.; Dickerson, S.; Kuyper, L. The Novel Cyclin Dependent Kinase Inhibitors, GW5181 and GW9499 Regulate Cell Cycle Progression and Induce Tumor-Selective Cell Death. Am. Assoc. Cancer Res. 1999, Apr 10-14.
141. Cheung, M.; Glennon, K. C.; Lackey, K. E.; Peel, M. R. Preparation of Arylmethyleneazaoxindoles as Protein Kinase Inhibitors. PCT Int. Appl. W09921859 A1 990506.
142. Misra, R. N.; Kimball, S. D.; Rawlins, D. B.; Webster, K. R.; Bursuker, I. Use of Pyrazolo [3,4-b] Pyridine as Cyclin Dependent Kinase Inhibitors. PCT Int. Appl. WO9930710 A1 990624.
143. Ruetz, S.; Woods-Cook, K.; Solf, R.; Meyer, T.; Zimmerman, J.; Fabbro, D. Effect of CGP 60474 on Cyclin Dependent Kinases, Cell Cycle progression and onset of Apoptosis in Normal and Transformed Cells. Cold Spring Harbor Winter Conference on Pathways to Cancer, Mar 11-14, 1998; Abstr. 38.
144. Furet, P.; Imbach, P.; Capraro, H.; Ruetz, S.; Meyer, T.; Zimmerman, J. Structure-Based Optimization of Olomoucine, a CDK1/2 Inhibitor. 216th ACS National Meeting, Boston, MA, Aug 23-27, 1998.
145. Boschelli, D. H.; Dobrusin, E. M.; Doherty, A. M.; Fattacy, A.; Fry, D. W.; Barvian, M. R.; Kallmeyer, S. T.; Wu, Z. Preparation of Pyrido[2,3-d]pyrimidines and 4-Aminopyrimidines as Inhibitors of Cellular Proliferation. PCT Int. Appl. WO 9833798 A2 980806.
146. Lundgren, K.; Price, S. M.; Excobar, J.; Huber, A.; O'Connor, P.; Chong, W.; Duvadie, R.; Li, L.; Chu, S. S.; Nonomiya, J.; Tucker, K.; Mroczkowski, B.; Lewis, C. Novel Cyclin-Dependent Kinase Inhibitors with Potent Growth Inhibitory Action. Am. Assoc. Cancer Res. 1999, Apr 10-14.
147. Kim, K. S.; Kimball, S. D.; Poss, M. A.; Misra, R. N.; Cai, Z.-W.; Rawlins, D. B.; Webster, K.; Hunt, J. T.; Han, W.-C. Aminothiazole Inhibitors of Cyclin Dependent Kinases. PCT. Int. Appl. WO9924416 A1 990520.
148. Kitagawa, M.; Okabe, T.; Ogino, H.; Matsumoto, H.; Suzuki-Takahashi, I.; Kokubo, T.; Higashi, H.; Saitoh, S.; Taya, Y.; Yasuda, H.; Ohba, Y.; Nishimura, S.; Tanaka, N.; Okuyama, A. Butyrolactone I, a Selective Inhibitor of CDK2 and CDC2 Kinase. Oncogene 1993, 8, 2425-2432.
149. Someya, A.; Tanaka, N.; Okuyama, A. Inhibition of Cell Cycle Oscillation of DNA Replication by a Selective Inhibitor of the CDC2 Kinase Family, Butyrolactone I, in Xenopus Egg Extracts. Biochem. Biophys. Res. Commun. 1994, 198, 536-545.
150. Nishio, K.; Ishida, T.; Arioka, H.; Kurokawa, H.; Fukuoka, K.; Nomoto, T.; Fukumoto, H.; Yokote, H.; Saijo, N. Antitumor Effects Of Butyrolactone-I, a Selective Cdc2 Kinase Inhibitor, On Human Lung-Cancer Cell-Lines. Anti-Cancer Res. 1996, 16, 3387-3395.
151. Zaharevitz, D.; Kunick, C.; Schultz, C.; Meijer, L.; Leost, M.; Gussio, R.; Senderowicz, A.; Lahusen, T.; Sausville, E. The Paullones, A Novel Class of Small Molecule Inhibitors of Cyclin-Dependent Kinases Am. Assoc. Cancer Res. 1999, Apr 10-14.
152. Okumura, E.; Sekiai, T.; Hisanaga, S.; Tachibana, K.; Kishimoto, T. Initial Triggering of M Phase in Starfish Oocytes: A Possible Novel Component of Maturation-Promoting Factor Besides CDC2 Kinase. J. Cell. Biol. 1996, 732, 125-135.
153. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A.; Meijer, L.; Kunick, C. Paullones, a Series of Cyclin-Dependent Kinase Inhibitors: Synthesis, Evaluation of CDK1/Cyclin B Inhibition, and in Vitro Antitumor Activity. J. Med. Chem. 1999, 42, 2909-2919.
154. Siavoshian, S.; Blottiere, H. M.; Cherbut, C.; Galmiche, J.-P. Butyrate Stimulates Cyclin D and p21 and Inhibits Cyclin-Dependent Kinase 2 Expression in HT-29 Colonic Epithelial Cells. Biochem. Biophys. Res. Commun. 1997, 232, 169-172.
155. Cui, C.-B.; Ubukata, M.; Kakeya, H.; Onose, R.; Okada, I.; Takahashi, K.; Isono, K.; Osada, H. J. Antibiot. 1996, 46, 216-219.
156. Ayer, W. A.; Attah-Poku, S. K.; Browne, L. M.; Orszansda, H. Can. J. Chem. 1987, 6,5, 765-769.
157. Nomoto, S.; Mori, K. Synthetic microbial chemistry. Part 30. Synthesis of Acetophthalidin, a Fungal Metabolite Which Inhibits the Progression of the Mammalian Cell Cycle. Liebigs Ann. Recueil. 1997, 4, 721-723.
158. Bojanowski, K.; Nishio, K.; Fukuda, M.; Larsen, A. K.; Saijo, N. Effect of Suramin on p34CDC2 Kinase In Vitro and in Extracts From Human H69 Cells: Evidence for a Double Mechanism of Action. Biochem. Biophys. Res. Commun. 1994, 203, 1574-1580.
159. Ip, C.; Hayes, C.; Budnick, R. M.; Ganther, H. E. Chemical Form of Selenium, Critical Metabolites and Cancer Prevention. Cancer Res. 1991, 51, 595-600.
160. Ip, C.; Ganther, H. E. Relationship Between the Chemical Form of Selenium and Anticarcinogenic Activity. In Cancer Chemoprevention; Wattenberg, L., Lipkin, M., Boone, C. W., Kellof, G. J., Eds.; CRC Press: Boca Raton, FL, 1992; pp 479-488.
161. Sinha, R.; Medina, D. Inhibition of CDK2 Kinase Activity by Methylselenocysteine in Synchronized Mouse Mammary Epithelial Tumor Cells. Carcinogenesis 1997, 18, 1541-1547.
162. Fahraeus, R.; Lane, D. P. INK4 Protein p16-Derived Peptides or Peptide Mimetics that Bind by Cyclin-Dependent Kinases, Inhibit Rb Protein Phosphorylation, and are Useful for Treating Hyperproliferative Disorders. PCT Int. Appl. WO 9711174 A1 970327.
163. Sasaki, S.; Hashimoto, T.; Obana, N.; Yasuda, H.; Uehara, Y.; Maeda, M. Design of New Inhibitors for CDC2 Kinase Based on a Multiple Pseudosubstrate Structure. Bioorg. Med. Chem. Lett. 1998, 8, 1019-1022.
164. Buckley, M. F.; Sweeney, K. J.; Hamilton, J. A.; Sini, R. L.; Manning, D. L.; Nicholson, R. I.; deFazio, A.; Watts, C. K.; Musgrove, E. A.; Sutherland, R. L. Expression and Amplification of Cyclin Genes in Human Breast Cancer. Oncogene 1993, 8, 2127-2133.
165. Gillett, C.; Fantl, V.; Smith, R.; Fisher, C.; Bartek, J.; Dickson, C.; Barnes, D.; Peters, G. Amplification and Overexpression of Cyclin D1 in Breast Cancer Detected by Immunohistochemical Staining. Cancer Res. 1994, 54, 1812-1817.
166. Bartkova, J.; Lukas, J.; Strauss, M.; Bartek, J. Cyclin D1 Oncoprotein Aberrantly Accumulates in Malignancies of Diverse Histogenesis. Oncogene 1995, 10, 775-778.
167. Wolfel, T.; Hauer, M.; Schneider, J.; Serrano, M.; Wolfel, C.; Klehmann-Hieb, E.; De Plaen, E.; Hankeln, T.; Meyer zum Buschenfelde, K. H.; Beach, D. A p16INK4a-Insensitive CDK4 Mutant Targeted by Cytolytic Lymphocytes in a Human Melanoma. Science 1995, 269, 1281-1284.
168. Wunder, J. S.; Eppert, K.; Burrow, S. R.; Gogkoz, N.; Bell, R. S.; Andrulis, I. L. Co-amplification and Overexpression of CDK4, SAS and MDM2 Occurs Frequently in Human Parosteal Osteosarcomas. Oncogene 1999, 18, 783-788.
169. Kamb, A. Role of a Cell Cycle Regulator in Hereditary and Sporadic Cancer. Cold Spring Harb. Symp. Quantum Biol. 1994, 59, 39-47.
170. Liggett, W. H., Jr.; Sidransky D. Role of the p16 Tumor Suppressor Gene in Cancer. J. Clin. Oncol. 1998, 16, 1197-1206.
171. Sherr C. J.; Roberts, J. M. CDK Inhibitors: Positive and Negative Regulators of G1-Phase Progression. Genes Dev. 1999, 13, 1501-1512.
172. Rane, S. G.; Dubus, P.; Mettus, R. V.; Galbreath, E. J.; Boden, G.; Reddy, E. P.; Barbacid, M. Loss of Cdk4 Expression Causes Insulin-deficient Diabetes and Cdk4 Activation Results in Beta-islet Hyperplasia. Nat. Genet. 1999, 22, 44-52.
173. Tsutsui, T.; Hesabi, B.; Moons, D. S.; Pandolfi, P. P.; Hansel, K. S.;
174. Van den Heuvel, S.; Harlow, E. Distinct Roles for Cyclin-dependent Kinases in Cell Cycle Control. Science 1993, 262, 2050-2054.
175. Cheng, M.; Olivier, P.; Diehl, J. A.; Fero, M.; Roussel, M. F.; Roberts, J. M.; Sherr, C. J. The p21(Cip1) and p27(Kip1) CDK 'Inhibitors' are Essential Activators of Cyclin D-dependent Kinases in Murine Fibroblasts. EMBO J. 1999, 18, 1571-1583.
176. McConnell, B. B.; Gregory, F. J.; Stott, F. J.; Hara, E.; Peters, G. Induced Expression of p16ink41 Inhibits Both CDK4 and CDK2 Associated Kinase Activity by Reassortment of Cyclin-CDK Inhibitor Complexes. Mot. Cell. Biol. 1999, 19, 1981-1989.
177. Quelle, D. E.; Zindy, F.; Ashmun, R. E.; Sherr, C. J. Alternate Reading Frames of the INK4a Tumor Suppressor Gene Encode Two Unrelated Proteins Capable of Inducing Cell Cycle Arrest. Cell 1995, 83, 993-1000.
178. Sharpless, N. E.; DePinho, R. A. The INK4A/ARF Locus and its Two Gene Products. Curr. Opin. Genet. Dev. 1999, 9, 22-30.
179. Larsen, C. J. Contribution of the Dual Coding Capacity of the p16INK4a/MTS1/CDKN2 Locus to Human Malignancies. Prog. Cell Cycle Res. 1997, 3, 109-124.
180. Zhang Y.; Xiong, Y.; Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppressor Pathways. Cell 1998, 92, 725-734.
181. Pomerantz, J.; Schreiber-Agus, N.; Liegeois, N. J.; Silverman, A.; Alland, L.; Chin. L.; Potes, J.; Chen, K.; Orlow, I.; Lee, H. W.; Cordon-Cardo, C.; DePinho, R. A. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53. Cell 1998, 92, 713-723.
182. Stott, F. J.; Bates, S.; James, M. C.; McConnell, B. B.; Starborg, M.; Brookes, S.; Palmero, I.; Ryan, K.; Hara, E.; Vousden, K. H.; Peters, G. The Alternate Product from the Human CDKN2A Locus, p14(ARF), Participates in a Regulatry Feedback Loop with p53 and MDM2. EMBO J. 1998, 17, 5001-5014.
183. Honda R.; Yasuda, H. Association of p19(ARF) with Mdm2 Inhibits Ubiquitin Ligase Activity of Mdm2 for Tumor Suppressor p53. EMBO J. 1999, 18, 22-27.
184. Tao, W.; Levine, A. J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Nati. Acad. Sci. U.S.A. 1999, 96, 6937-6941.
185. Murphy, M.; Stinnakre, M. G.; Senamaud-Beaufort, C.; Winston, N. J.; Sweeney, C.; Kubelka, M.; Carrington. M.; Brechot, C.; Sobczak-Thepot, J. Delayed Early Embryonic Lethality Following Dispruption of the Murine Cyclin A2 Gene. Nat. Genet. 1997, 15, 83-86.
186. Fang, F.; Orend, G.; Watanabe, N.; Hunter, T.; Ruoslahti, E. Dependence of Cyclin E-CDK2 Kinase Activity on Cell Anchorage. Science 1996, 277, 499-502.
187. Orend, G.; Hunter, T.; Ruoslahti, E. Cytoplasmic Displacement of Cyclin E-cdk2 Inhibitors p21Cip1 and p27Kip1 in Anchorage Independent Cells. Oncogene 1998, 16, 2575-2583.
188. Chen, Y. N.; Sharma, S. K.; Ramsey, T. M.; Jiang, L.; Martin, M. S.; Baker, K.; Adams, P. D.; Bair, K. W.; Kaelin, W. G. Jr. Selective Killing of Transformed Cells by Cyclin/Cyclin-dependent Kinase 2 Antagonists. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4221-4223.
189. Hunter, T. 1001 Protein Kinases Redux - Towards 2000. Cell 1994, 5, 367-376.